Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Issue 2 (November 2017)

• Record Type: Journal Article
• Authors: Yeboa, Debra Nana; Rutter, Charles E.; Park, Henry S.; Lester-Coll, Nataniel H.; Corso, Christopher D.; Mancini, Brandon R.; Bindra, Ranjit S.; Contessa, Joseph; Yu, James B.
• Is Part Of: Radiotherapy and oncology. Volume 125:Issue 2(2017:Nov.)
• Page Start: 258
• Page End: 265
• Publication Date: 2017-11
• Subjects: Central nervous system -- Anaplastic glioma -- Chemoradiotherapy -- Combined modality -- Outcomes; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2017.09.027
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background and purpose: The role of concurrent chemoradiotherapy (CRT) for anaplastic gliomas is undefined and patterns of care are under-reported. To address the knowledge gap, we examined use of CRT for grade III gliomas compared to radiotherapy (RT) alone. Material and methods: In an observational study design cohort from the National Cancer Database, we identified 4437 adult patients receiving surgery followed by either CRT or RT for supratentorial anaplastic glioma in 2003–2011. Univariable and multivariable logistic regression analyses were used to assess factors associated with use of CRT. Overall survival (OS) was assessed by the Kaplan–Meier analysis with log-rank tests, Cox proportional hazards regression modeling, and propensity score matching. Results: Receipt of CRT (vs. RT) was associated with recent year of diagnosis (OR for 2011 (vs. 2003) 3.36, 95% CI 2.49–4.54) and having astrocytoma (vs. oligodendroglioma) (OR 1.37, 95% CI 1.15–1.63). Patients receiving CRT had a lower adjusted hazard of death (hazard ratio 0.72, 95% CI 0.65–0.79). Outcomes were worse for patients ≥60 (HR 6.94, 95% CI 6.09–7.91) and astrocytomas (HR 2.08, 95% CI 1.85–2.34). Conclusion: Use of concurrent CRT is associated with more recent year of diagnosis and improved survival relative to RT alone.